AI Stock Monitor
AMGN - Amgen
Amgen is a North America covered company in The Hedge Book research universe.
Public company · North America · Healthcare · Biotechnology · Dow constituent
0 followers · Follow to include this stock in your daily 9:30 AM Central watchlist email.
NASDAQ · Healthcare · Research updated · Market data updated Research and source refreshes run four times daily. The timestamps above identify the latest successful research and market-data updates.
Hedge Score
75
/100
Price History
AMGN chart
AI-Assisted Chart Analysis
Amgen technical analysis
Calculated from verified chart history for the selected tenor; no news or fundamental assumptions are used.
Mixed trend: the latest level is above its 20-period average, without full long-term confirmation.
RSI is 64, a neutral reading. Above 70 can signal extension; below 30 can signal exhaustion.
The first technical watch zone is 412.84. A break below 375.65 invalidates the near-term support setup.
The first resistance/watch zone is 478.48. A confirmed break above 478.48 supports continuation.
Annualized realized volatility is +33.4%. Maximum lookback drawdown is -15.4%, from a high-water mark of 444.12 to 375.65.
Potential levels are conditional chart scenarios, not personalized advice or instructions to buy or sell.
How To Read This Stock Brief
Higher means the current research setup is stronger across signal, confidence, catalysts, risk balance, and market context. Lower means the setup is weaker or less supported.
Higher confidence means the evidence is more consistent and relevant. It does not mean the stock has that percentage chance of going up.
Bullish, Bearish, or Neutral is the current AI research stance. It is designed to help you ask better questions, not to replace your decision process.
This shows how signed-in users are voting. It is useful sentiment context, not proof that the crowd is right.
What Changed Today
- Yahoo Finance delayed market data reported AMGN at 462.17 USD; the latest daily move rose +0.38%. This is a verified market-price signal only and does not by itself confirm a change in company fundamentals.
Why It Matters
- The verified +0.38% daily move is current market context for Amgen.
- It can affect near-term sentiment, but price action alone does not establish a change in earnings, asset quality, competitive position, valuation, catalysts, or risks.
- Those require a separately sourced filing or company update.
AI Opinion
- Read: The current signal is Bullish, driven by the company's ability to consistently beat earnings expectations and raise forward guidance, which indicates strong operational execution.
- Evidence: The evidence is robust, supported by official Q3 earnings reports and consistent institutional capital inflows, though the stock's performance must be balanced against the inherent risks of drug development and regulatory scrutiny.
- Uncertainty: While the dividend growth is an attractive feature for income-focused investors, the primary driver for future valuation expansion will be the successful commercialization of the current pipeline and the ability to maintain margins in a competitive biotech landscape.
- Watch: A shift in this view would require evidence of a material slowdown in revenue growth, a failure in key late-stage clinical trials, or a significant deterioration in the balance sheet due to aggressive M&A activity.
Key Risks
- Regulatory and FDA scrutiny remains a persistent risk, as evidenced by recent warning letters, which can delay product launches or impact the commercialization of existing therapies.
- Margin pressure could emerge if R&D costs for the experimental pipeline escalate faster than revenue growth from established products, potentially impacting free cash flow.
- The competitive landscape in the biotechnology sector is intense; failure to maintain market share against biosimilars or new entrants in key therapeutic areas could lead to revenue stagnation.
- Macroeconomic factors, including potential changes in drug pricing legislation or healthcare reimbursement policies, could negatively impact the company's long-term profitability.
Upcoming Catalysts
- Future earnings calls and guidance updates will be the primary mechanism for confirming if the current momentum in revenue growth is sustainable.
- Clinical trial readouts for the experimental pipeline will serve as binary events that could significantly alter the company's long-term growth prospects.
- Company filings regarding capital allocation, including potential M&A activity or further dividend adjustments, will provide insight into management's strategic priorities.
- Updates on the commercial performance of key growth drivers, particularly in the rare disease and cardiovascular segments, will be critical for validating the company's diversification strategy.
Upcoming Events
No verified update available
Last Updated
Sources and verification
Each generated research claim remains linked to its supporting update. Primary evidence comes from filings, company materials, or regulators; secondary evidence provides additional context.
- Published stock briefSecondary sourceReportedAmgen's new drug could mean fewer shots for obesity patients · Published 2026-11-09 10:01:28Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedAmgen’s Dividend Has Grown 800% Since 2011. Here’s What It Pays Today - Yahoo Finance · Published 2026-11-09 10:01:28Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedAmgen’s Dividend Has Grown 800% Since 2011. Here’s What It Pays Today · Published 2026-11-09 10:01:28Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceAnalyst OpinionAmgen Inc | AMG | Stock - Morningstar · Published 2026-11-09 10:01:28Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReported5 Worst Dow Stocks To Buy According to Analysts · Published 2026-11-09 10:01:28Open verification sourceSupports: Published stock brief
Market-data attributionYahoo Finance delayed market data · provider detailsMarket prices are supporting signals only and do not establish the research conclusion.
Community View
Sign in with Google to vote once per stock.
Total votes: 0
Disclaimer
The Hedge Book provides AI-assisted educational market research. It is not a registered investment adviser, broker, dealer, or financial planner. Content may contain errors and should be independently verified. Do not treat this page as personalized advice to buy, sell, or hold any security.